Similarly, Lin et al. (2021) used a panel of fourteen frequently mutated genes in breast cancer and found that ctDNA positivity after neoadjuvant therapy was associated with significantly inferior RFS in estrogen receptor-positive HER2− breast cancer, though exact statistical significance was not reported [49]. This evidence concerns the gene ESR1 and breast cancer.